SLBST Pharma uses a novel approach to treating endometriosis by normalizing the dysregulated immune response characteristic of this systemic inflammatory disease. Endometriosis, which affects one-in-ten women, is vastly undertreated. None of the existing hormonal medications cure the underlying disease. Women with endo use 3x the number of opioids and 2x the number of antidepressants, compared to a matched control. SLBST is repurposing a well-known drug with a decades-long safety record, for this new indication. Our therapy has comparable safety to existing first line treatments and, we believe, comparable effectiveness to existing second line treatments, with significantly fewer adverse effects. Success in clinical trials will position our therapy to become the new standard of care for endo. In a Pre-IND meeting with the FDA last year, we received a green light to submit an IND application beginning with a Phase 2 study. We are currently doing the development work to manufacture the clinical batch of medications, which should position us to begin enrolling patients in early 2024.